The week in health tech, explained in plain English.Get the free newsletter →
June 11, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

R1 RCM Names Ex-Humana CTO Eric Tagliere as CIO

R1 RCM has named Eric Tagliere chief information officer, the revenue cycle management company announced in a June 9 release reported by Becker's Hospital Review. Tagliere most recently served as chief technology officer at Humana, where he led technology operations and advanced the insurer's cloud and modernization strategy.

In his new role, Tagliere will lead R1's global technology organization. The hire signals R1's intent to apply payer-side technology discipline to the complex work of hospital billing, claims, and collections, an area under pressure as health systems fight margin strain and rising denials.

The move reflects a broader pattern of revenue cycle vendors recruiting executives from large payers and cloud-focused roles. As R1 expands its global footprint and leans further into automation and AI for billing workflows, a CIO with experience modernizing infrastructure at a national insurer like Humana gives the company a leader familiar with both scale and the payer logic that drives reimbursement.

More in Finance

Finance

AstraZeneca GLP-1 Pill Shows Promise in Obesity Trials

AstraZeneca's oral GLP-1 drug showed promise in mid-stage obesity and diabetes trials, but its standing against rival pills remains unclear.

Why it matters: An effective GLP-1 pill could broaden access to weight-loss and diabetes treatment and intensify competition in a market headed past $100 billion.

Finance

Incyte Pays $1.25B for Vega and Its Bleeding Disorder Drug

Incyte is acquiring Vega Therapeutics for $1.25 billion to gain a late-stage von Willebrand disease drug as patent expiration looms for its top product, Jakafi.

Why it matters: The deal shows how biopharma companies race to backfill pipelines and diversify ahead of major patent cliffs.

Finance

GSK to Buy Cancer Drugmaker Nuvalent for $10.6 Billion

GSK is acquiring Nuvalent for $10.6 billion to add late-stage targeted lung cancer drugs, the latest in a run of biopharma deals.

Why it matters: The deal shows how big drugmakers are spending billions on precision oncology to refill pipelines ahead of patent cliffs.